


Mark Chang

Classical and Adaptive Clinical Trial Designs Using ExpDesign Studio™



Includes the
Professional Version 5.0 of
ExpDesign Studio™ software

 **WILEY**

R914.2
C456

CLASSICAL AND ADAPTIVE CLINICAL TRIAL DESIGNS USING EXPDESIGN STUDIO™

Mark Chang

Millennium Pharmaceuticals, Inc.



E2008001586

A JOHN WILEY & SONS, INC., PUBLICATION

光盘壹张

Copyright © 2008 by John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.
Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Chang, Mark.

Classical and adaptive clinical trial designs using ExpDesign Studio™ / Mark Chang.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-27612-9 (cloth/cd)

1. Drugs—Testing—Computer simulation. 2. Adaptive sampling (Statistics) 3. Clinical trials—Data processing. I. Title.

[DNLM: 1. Drugs, Investigational. 2. Research Design. 3. Clinical Trials as Topic—methods. 4. Software. QV 771 C4565c 2008]

RM301.27.C47 2008

615'.190113—dc22

2008001358

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

**CLASSICAL AND ADAPTIVE
CLINICAL TRIAL DESIGNS
USING EXPDESIGN STUDIO™**

PREFACE

Drug development is shifting from the classical approaches to more dynamic or adaptive approaches. The pharmaceutical industry and the U.S. Food and Drug Administration (FDA) has been seeking efficient methods of drug development as indicated in the FDA's critical path document. Many people believe that the innovative approach of adaptive design is a major pathway to success in drug development in today's challenging drug development environment.

In a book that I co-authored, *Adaptive Design Methods in Clinical Trials* (Chow and Chang, 2006), various adaptive design methods were introduced. Six months later I authored a second book, *Adaptive Design Theory and Implementation Using SAS and R* (Chang, 2007a), which provided in-depth and unified theory regarding adaptive designs and implementations, with many trial examples. These two books require a strong statistical background and clinical trial experience.

However, based on feedback from recent adaptive design workshops and conferences, I realize that there are many practitioners who are very good at strategic thinking and solution of practical problems but little interested in or lacking time to study the theory. Although I have kept the SAS and R program units as small as possible, with a clear logic flow from my previous books, there are still minimal requirements for knowledge of SAS or R. Also, many statisticians who are familiar with SAS would prefer to have software with a graphic user interface that can provide user-friendly tools for both classical and adaptive designs and monitoring. Among other options, I believe that ExpDesign Studio® fits the practical needs and provides a one-stop-shopping experience (CTriSoft, www.CTriSoft.net). This book, which avoids dealing with theory, is complementary to the two books mentioned earlier. Readers can jump-start to adaptive design without difficulty if they have one or two years of clinical trial design experience. However, for readers interested in the mathematical details, the mathematical notes at the end of each chapter will provide the key formulations for each method, or they can review *Adaptive Design Theory and Implementation Using SAS and R* (Chang, 2007a) for an in-depth understanding of the theory and algorithms for computer implementation.

ExpDesign is commercial software used by major pharmaceutical companies, universities, and research institutes worldwide. With ExpDesign you can design a classical or adaptive design literally in two minutes if you have the parameters ready. The ExpDesign enterprise version can also generate SAS and R code for an adaptive design.

The book has been written with practitioners in mind. It is not intended to teach adaptive design theory nor to function as a simple software user manual. The objective of the book is to demonstrate the use of ExpDesign in trial design, to assist strategic decision making, and to help solve issues related to classical and adaptive trials. It is written as a tutorial, a self-learning textbook (see the Self-Study and Practice Guide following the preface). Readers are expected to master the basic adaptive trial techniques in about one week. The book, together with the software, makes learning easy and fun. The accompanying software is a fully professional version of ExpDesign Studio 5.0, not a typical trial version. The book and the software, covering both classical and adaptive designs, can be used to leverage drug development in such a way that statisticians and other parties have more freedom and time to focus on the real issues, not the calculation or theory. The book is organized as follows:

In Chapter 1 we present an overview of the software ExpDesign Studio, provide a feeling for what it can do in trial designs, demonstrate simple design examples from classical, group sequential, adaptive, and other trials with ExpDesign Studio, and explain the basic operation of the software.

Chapter 2 provides an overview of a variety of clinical trial designs, their advantages and disadvantages, and when different classical and adaptive designs can be used.

Chapter 3 focuses on classical designs. After a discussion as to how sample size should be determined and on the variety of factors that affect the decision as to what sample size to use in a trial, examples are given on how to utilize ExpDesign to calculate sample size. Among nearly 150 sample-size calculation methods available in ExpDesign, the examples are carefully chosen to include a variety of designs, types of endpoints, and phases of clinical trials.

In Chapter 4 we discuss group sequential design (GSD), a commonly used and probably the simplest adaptive design. Starting with an overview of group sequential design, how to design and monitor a GSD trial using ExpDesign Studio is discussed. Finally, the key mathematic formulations for GSD are summarized for those interested in the mathematical details.

In Chapter 5 we discuss adaptive trial designs and introduce the stagewise test statistic and stopping rules. Interim analysis and trial monitor tools such as conditional power are described. We also discuss how to use ExpDesign Studio to design sample-size reestimation, drop-loser, biomarker-adaptive, response-adaptive randomization, and adaptive dose-finding trials. The mathematic formulations are summarized in the final section.

In Chapter 6 we discuss the specific design of early-phase oncology trials, because of its uniqueness. It includes multiple-stage single-arm design and dose-escalation design for maximum tolerated dose and show how to use ExpDesign to design oncology trials and how to compare and evaluate different designs based on their operating characteristics.

In Chapter 7 we focus on adaptive trial monitoring. The importance of trial monitoring and mathematic tools for monitoring is discussed, and how to use

the trial monitor in ExpDesign to monitor an adaptive trial is described in detail using real-world examples.

In Chapter 8 we present a computer simulation approach in which the test statistic is the same as the classical design. The simulation module in ExpDesign allows for any combinations of the following adaptations: early futility and/or efficacy stopping, sample-size reestimation, drop-loser, and response-adaptive randomization based on the dose-response relationship. Step-by-step instructions are presented with trial examples.

In Chapter 9 we discuss how to get further assistance from ExpDesign. ExpDesign provides many toolkits for design, monitoring, and analysis of trials: the graphical calculator, which allows you to plot complicated mathematical expressions, the probability calculator for probability and percentile calculations, and the confidence interval calculator for exact confidence interval calculations. For advanced users, we also discuss how to use ExpDesign to generate univariate and multivariate data that can be used for various purposes of trial design, monitoring, and risk assessment.

In Chapter 10 we present notes on technique for nearly 100 methods for sample-size calculation, grouped by the number of arms, the trial endpoint, and the analysis basis. We describe the purpose of each method, information about the methods, such as when and how to use each one, the formula and/or references, and the assumptions or limitations of the methods.

Appendix A is about validation of ExpDesign. Several reviewers have indicated the importance of software validation and suggested including the validation information in the book. The validation document is also meant to support pharmaceutical end users to meet FDA 21 CFR part 11 requirements.

Installation instructions for the software CD and the license agreement appear at the end of the pages.

MARK CHANG

Lexington, Massachusetts
Winter 2007
www.Statisticians.org

SELF-STUDY AND PRACTICE GUIDE

Day 1

- ExpDesign Studio 5.0 Installation (10 minutes)
- Chapter 1: ExpDesign Studio (30 minutes of reading and practice)
- Chapter 2: Clinical Trial Design (3 hours of reading)
- Chapter 3: Classical Trial Design (4 hours of reading and practice)
- Chapter 10: Classical Design Method Reference (15 minutes of reading)
- Appendix A: Validation of ExpDesign Studio (15 minutes of reading)

Day 2

- Chapter 4: Group Sequential Trial Design (8 hours of reading and practice) The classical group sequential design and simplest adaptive design are discussed. Make sure you understand the basic concepts of group sequential design, such as the notion of early stopping, error inflation due to multiple looks, different types of stopping boundaries, and different scales for stopping boundaries. Go through all the trial examples using ExpDesign; it helps you get “hands-on” experience. Trial monitoring requires your effort, which will give you the feeling of running an actual group sequential trial.

Days 3

- Chapter 5: Adaptive Trial Design (8 hours of reading and practice)
- You will learn various adaptive designs. Make sure that you understand the three commonly used statistical methods. Again, go through the trial practice using ExpDesign for hands-on experiences. The practices are straightforward and should take no more than 20 minutes each.

Day 4

- Chapter 6: Adaptive Trial Monitoring (8 hours of reading and practice) Adaptive trial monitoring can be considered as the most challenging part

of this book. It is about how you make actual adaptations for an ongoing trial based on the design without undermining the validity and integrity of the trial. Play around with the trial examples using ExpDesign, and spend extra time if needed.

Day 5

- Chapter 7: Oncology Adaptive Trial Design (5 hours of reading and practice)
- Chapter 8: Adaptive Trial Simulator (2 hours of optional reading and practice)
- Chapter 9: Further Assistance with ExpDesign Studio (1 hour of reading and practice)

The mathematical notes in Chapters 3, 4, and 7 are not meant to be studied in your first reading; rather, they are for future reference. Similarly, Chapter 10 and Appendix A can be read as needed.

CONTENTS

Preface	xiii
Self-Study and Practice Guide	xvii
1 ExpDesign Studio	1
1.1 Introduction	1
1.2 How to Design a Trial Using ExpDesign Studio	3
1.2.1 How to Design a Classical Trial	4
1.2.2 How to Design a Group Sequential Trial	4
1.2.3 How to Design an Adaptive Trial	5
1.2.4 How to Run Adaptive Trial Simulations	7
1.2.5 How to Design a Multistage Trial	9
1.2.6 How to Design a Dose-Escalation Trial	10
1.3 ExpDesign Menus	11
2 Clinical Trial Design	14
2.1 Introduction	14
2.2 Classical Clinical Trial Design	14
2.2.1 Substantial Evidence	15
2.2.2 Clinical Trial Endpoint	15
2.2.3 Confirmatory Trials	15
2.2.4 Exploratory Trials	16
2.2.5 Multicenter Trials	16
2.2.6 Trials to Show Superiority	16
2.2.7 Trials to Show Equivalence or Noninferiority	16
2.2.8 Trials to Show a Dose-Response Relationship	17
2.2.9 Parallel Design	17
2.2.10 Crossover Design	17
2.2.11 Factorial Design	18
2.3 Selection of a Trial Design	18
2.3.1 Balanced Versus Unbalanced Designs	18
2.3.2 Crossover Versus Parallel Designs	19
2.3.3 Dose Escalation Versus Titration Designs	21
2.3.4 Bioavailability Versus Bioequivalence Designs	21

2.3.5	Equivalence Versus Bioequivalence	22
2.3.6	Sample-Size Determination	23
2.4	Adaptive Clinical Trial Design	23
2.4.1	Group Sequential Design	24
2.4.2	Sample-Size Reestimation Design	25
2.4.3	Drop-Loser Design	25
2.4.4	Response-Adaptive Randomization Design	25
2.4.5	Adaptive Dose-Escalation Design	26
2.4.6	Biomarker-Adaptive Design	26
2.4.7	Multistage Design of Single-Arm Trials	26

3 Classical Trial Design

27

3.1	Introduction	27
3.1.1	Hypothesis Test	27
3.1.2	Importance of Sample-Size Calculation	28
3.1.3	Factors Affecting Sample Size	29
3.1.4	Avoiding Under- or Overpowered Designs	29
3.2	How to Calculate Sample Size Using ExpDesign	30
3.2.1	Testing the Mean Difference Between Two Groups	30
3.2.2	Testing the Proportion Difference Between Two Groups	30
3.2.3	Testing the Survival Difference Between Two Groups	31
3.2.4	Testing the Survival Difference with a Follow-up Period	32
3.2.5	Exact Test for a One-Sample Proportion	33
3.2.6	McNemar's Test for Paired Data	35
3.2.7	Noninferiority Test for Two Means	35
3.2.8	Bioequivalence Test for Two Means	36
3.2.9	Bioequivalence Test for Two Means of Lognormal Data	37
3.2.10	Equivalence Test Based on the Ratio of Two Means	38
3.2.11	Precision Method for the Mean Difference for a Paired Sample	39
3.2.12	Mantel-Haenszel Test for an Odds Ratio with Two Strata	39
3.2.13	Pearson's Chi-Square Test for Rate Difference	41
3.2.14	One-Way ANOVA for Parallel Groups	41
3.2.15	Dose-Response Trial for a Myocardial Infarction	42
3.3	Mathematical Notes on Classical Design	43
3.3.1	Large-Sample-Size Calculation for Classical Design	43

- 3.3.2 Commonly Used Terms and Their Mathematical Expressions 45
- 3.3.3 Relationship Between Enrollment Rate and Number of Events 48

4 Group Sequential Trial Design 51

- 4.1 Introduction 51
- 4.2 Basics of Group Sequential Design 51
- 4.3 How to Design Sequential Trials Using ExpDesign 53
 - 4.3.1 Design Featuring Early Efficacy Stopping for Two Means 54
 - 4.3.2 Design Featuring Early Futility Stopping for a Proportion 56
 - 4.3.3 Design Featuring Early Stopping for a Survival Endpoint 58
 - 4.3.4 Design Featuring Early Stopping for Paired Proportions 60
- 4.4 How to Monitor a Group Sequential Trial Using ExpDesign 62
 - 4.4.1 Need for Trial Monitoring 62
 - 4.4.2 Techniques for Monitoring a Sequential Trial 63
 - 4.4.3 How to Monitor a Trial Using ExpDesign 64
- 4.5 Mathematical Notes on Sequential Trial Design 68
 - 4.5.1 Unified Formulation for Sequential Trial Design 68
 - 4.5.2 Calculation of Conditional Probability 72
 - 4.5.3 Conditional and Predictive Power and RCI for Trial Monitoring 73
 - 4.5.4 Bias-Adjusted Estimates 74

5 Adaptive Trial Design 75

- 5.1 Introduction 75
- 5.2 Basics of Adaptive Design Methods 75
- 5.3 How To Design a Sample-Size Reestimation Trial Using ExpDesign 77
 - 5.3.1 Sample-Size Adjustment Based on the Effect-Size Ratio 78
 - 5.3.2 Sample-Size Adjustment Based on Conditional Power 78
 - 5.3.3 Adaptive Design for an Acute Ischemic Stroke Trial 78
 - 5.3.4 Adaptive Design for an Asthma Study 81
 - 5.3.5 Adaptive Design for an Oncology Trial 84
 - 5.3.6 Noninferiority Design with a Binary Endpoint 86

- 5.4 How to Design a Drop-Loser Trial Using ExpDesign 90
 - 5.4.1 Drop-Loser Mechanism 90
 - 5.4.2 Seamless Design of an Asthma Trial 90
- 5.5 How to Design a Trial Using a Classifier Biomarker 93
 - 5.5.1 Biomarker Classifications 93
 - 5.5.2 Biomarker-Adaptive Design 94
- 5.6 How to Design a Play-the-Winner Trail Using ExpDesign 95
 - 5.6.1 Randomized Play-the-Winner Design 96
 - 5.6.2 Adaptive Randomization with a Normal Endpoint 98

6 Adaptive Trial Monitoring 103

- 6.1 Introduction 103
- 6.2 Error-Spending Approach 103
- 6.3 How to Recalculate Stopping Boundaries Using ExpDesign 105
- 6.4 Conditional Power and the Futility Index 109
- 6.5 How to Reestimate Sample Size Using ExpDesign 112
 - 6.5.1 Calculating Conditional Power Using ExpDesign 112
 - 6.5.2 Reestimating Sample Size Using ExpDesign 113
- 6.6 Trial Examples 114
 - 6.6.1 Changes in Number and Timing of the Analyses 114
 - 6.6.2 Recursive Two-Stage Adaptive Design 119
 - 6.6.3 Conditional Power and Sample-Size Reestimation 119

7 Oncology Adaptive Trial Design 123

- 7.1 Multistage Trial Design 123
 - 7.1.1 Introduction 123
 - 7.1.2 How to Design a Multistage Design Using ExpDesign 124
- 7.2 Dose-Escalation Trial Design 129
 - 7.2.1 Introduction 129
 - 7.2.2 Bayesian Continual Reassessment Method 134
 - 7.2.3 How to Design a Dose-Escalation Trial Using ExpDesign 135
- 7.3 Dose-Escalation Trial Monitoring Using CRM 141
- 7.4 Mathematical Notes on Multistage Design 143
 - 7.4.1 Decision Tree for a Multistage Trial 143
 - 7.4.2 Two-Stage Design 144
 - 7.4.3 Three-Stage Design 145
- 7.5 Mathematical Notes on the CRM 146
 - 7.5.1 Probability Model for Dose-Response 146

- 7.5.2 Prior Distribution of a Parameter 147
- 7.5.3 Likelihood Function 147
- 7.5.4 Reassessment of a Parameter 147
- 7.5.5 Assignment of the Next Patient 147

8 Adaptive Trial Simulator 149

- 8.1 Adjusting the Critical Region Method 149
- 8.2 Classical Design with Two Parallel Treatment Groups 151
- 8.3 Flexible Design with Sample-Size Reestimation 157
- 8.4 Design with Random-Play-the-Winner Randomization 160
- 8.5 Group Sequential Design with One Interim Analysis 161
- 8.6 Design Permitting Early Stopping and Sample-Size Reestimation 162
- 8.7 Classical Design with Multiple Treatment Groups 165
- 8.8 Multigroup Trial with Response-Adaptive Randomization 165
- 8.9 Adaptive Design Featuring Dropping Losers 166
- 8.10 Dose-Response Trial Design 168
- 8.11 Dose-Escalation Design for an Oncology Trial 168

9 Further Assistance from ExpDesign Studio 172

- 9.1 ExpDesign Probability Functions 172
- 9.2 Virtual Trial Data Generation Using ExpDesign Randomizer 177
 - 9.2.1 Random Number Generation Using ExpDesign 177
 - 9.2.2 How to Generate a Random Univariate Using ExpDesign 177
 - 9.2.3 How to Generate a Random Multivariate Using ExpDesign 179
 - 9.2.4 How to Generate a Random Multibinomial Using ExpDesign 181
- 9.3 ExpDesign Toolkits 182
 - 9.3.1 Graphic Calculator 183
 - 9.3.2 Statistical Calculator 185
 - 9.3.3 Confidence Interval Calculator 185

10 Classical Design Method Reference 187

- 10.1 Single-Group Design 187
 - 10.1.1 One/Paired-Sample Hypothesis Test for the Mean 187
 - 10.1.2 One/Paired-Sample Hypothesis Test for the Proportion 189
 - 10.1.3 One/Paired-Sample Hypothesis Test for Others 190
 - 10.1.4 Paired-Sample Equivalence Test for the Mean 192
 - 10.1.5 Paired-Sample Equivalence Test for the Proportion 193

10.1.6	One-Sample Confidence Interval for the Mean	193
10.1.7	One-Sample Confidence Interval for the Proportion	195
10.1.8	One-Sample Confidence Interval for Others	196
10.2	Two-Group Design	196
10.2.1	Two-Sample Hypothesis Test for the Mean	196
10.2.2	Two-Sample Hypothesis Test for the Proportion	199
10.2.3	Two-Sample Hypothesis Test for Others	202
10.2.4	Two-Sample Equivalence/Noninferiority Test for the Mean	205
10.2.5	Two-Sample Equivalence/Noninferiority Test for the Proportion	207
10.2.6	Two-Sample Equivalence/Noninferiority Test for Survival	207
10.2.7	Two-Sample Confidence Interval for the Mean	208
10.2.8	Two-Sample Confidence Interval for the Proportion	208
10.3	Multigroup Trial Design	209
10.3.1	Multisample Hypothesis Test for the Mean	209
10.3.2	Multisample Hypothesis Test for the Proportion	211
10.3.3	Multisample Hypothesis Test for Others	212
10.3.4	Multisample Confidence Interval for Others	213

Afterword	214
------------------	------------

Appendix A: Validation of ExpDesign Studio	215
---	------------

A.1	Validation Process for ExpDesign Studio	216
A.1.1	Algorithm Validation	216
A.1.2	Statistical Outcome Validation	216
A.1.3	Criteria for Passing Validation	217
A.1.4	Input and GUI Validation	217
A.2	Validation of the Classical Design Module	217
A.3	Validation of the Group Sequential Design Module	221
A.3.1	Stopping Boundary and Type I Error Rate Validation	221
A.3.2	Power and Sample-Size Validation	221
A.4	Validation of the Adaptive Design Module	224
A.4.1	Stopping Boundary and Type I Error Rate Validation	224
A.4.2	Validation of Adaptive Design Monitoring	226
A.5	Validation of the Multistage Design Module	226
A.6	Validation of the Traditional Dose-Escalation Design Module	228
A.6.1	Validation of the Traditional Escalation Rule	228

A.6.2	Validation of the Bayesian Continual Reassessment Method	228
A.7	Validation of the Trial Simulation Module	228
A.8	Validation of the Randomizer	228
A.9	Validation of the ExpDesign Toolkits	229
A.10	Computer Programs for Validations	231
A.10.1	SAS Macro for Three-Stage Design Validation	231
A.10.2	Traditional 3 + 3 Escalation Design Validation	232
A.10.3	SAS Program for CRM Validation	232
Appendix B: Sample-Size Calculation Methods: Classical Design		235
References		240
Index		251
System Requirements, Software Installation, and Software License Agreement		259

1 ExpDesign Studio

1.1 INTRODUCTION

ExpDesign Studio (ExpDesign) is an integrated environment for designing experiments or clinical trials. It is a powerful and user-friendly statistical software product that has seven integrated main components: classical design (CD), sequential design (SD), multistage design (MSD), dose-escalation design (DED), adaptive design (AD), adaptive trial monitoring (ATM), and dose-escalation trial monitoring (DTM) modules. In addition, the ExpDesign randomizer can generate random variates from a variety of distributions. The ExpDesign toolkit provides features for distributional calculation, confidence intervals, and function and data plotting (Figure 1.1).

Classical trials are the most commonly used in practice. ExpDesign provides nearly 150 methods for sample-size calculations in CD for different trial designs. It includes methods for single-, two-, and multiple-group designs, and for superiority, noninferiority, and equivalence designs with various endpoints. See the list of classical design methods in Appendix B.

Group sequential trials are advanced designs with multiple analyses. A group sequential trial is usually a cost-effective design compared to a classical design. SD covers a broad range of sequential trials with different endpoints and different types of stopping boundaries.

A multistage design is an exact method for group sequential trials with a binary response, whereas group sequential design uses an asymptotic approach. MSD provides three optimal designs among others: MinMax, MinExp, and MaxUtility, which minimize the maximum sample size, minimize the expected sample size, and maximize the utility index, respectively.

A dose-escalation trial in aggressive disease areas such as oncology has unique characteristics. Due to the toxicity of the testing drug, researchers are allowed to use fewer patients to obtain as much information as possible about the toxicity profile or maximum tolerable dose. By means of computer simulations, DED provides researchers with an efficient way to search for an optimal design for dose-escalation trials with a variety of criteria. It includes traditional escalation rules, restricted escalation rules, two-stage